## THERANOSTICS PRELIMINARY POSTER LISTING

**Omar Alonso**  
Clinical value of 68Ga-PSMA in patients with prostate cancer and biochemical recurrence using a tri-modality PET/CT-MR (3.0 T) system with a dedicated shuttle.

**Adeola Ayoola**  
Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): safety, efficacy and survival outcomes from the South Australian Registry

**Sanjana Ballal**  
Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in treatment of patients with castration resistant prostate cancer

**Zsolt Baranyai**  
Formation kinetics of M(III)DOTA complexes in aqueous solution and water-€”ethanol mixtures.

**Makrem Ben Reguiga**  
INTERACTIONS OF 177LU-DOTATATE WITH PHARMACEUTICAL VEHICLES AND PEPTIDES

**Philip J Blower**  
New tris(hydroxypyridinone) chelators for 68Ga PET imaging

**Philip J Blower**  
One step kit labelling for PET imaging of prostate cancer using 68Ga-THP-PSMA

**Dilip Boddeti**  
An Unusual uptake of 68Ga-DKFZ-PSMA-11 activity by gall bladder during prostate cancer imaging.

**Wouter AP Breeman**  
Requirements on Specific Activity (SA) of 177Lu to Radiolabel DOTA-peptides for PRRT. Studies on Labeling a Typical Formulation of 0.1 mg DOTA-PSMA-617 (=0.1 µmoles) with 4 GBq 177Lu at Various SA of 177Lu

**Wouter AP Breeman**  
Dose-finding studies of 177Lu-DOTA-peptides for PRRT. Studies on formulation by varying Specific Activity (SA) of 177Lu-DOTA-peptides as a tool to optimize activity at constant amount of peptide

**Liesl Celliers**  
68Ga-pentixafor PET CTÂ for CXCR4 imaging of non-small cell lung cancer â€” initial findings in comparison with 18F-fluorodeoxyglucose

**Zejun Chen**  
99mTc-MIBI Dual-phase Imaging with Hybrid SPECT/CT for the Diagnosis of Rare Parathyroid Carcinoma

**Bonnie Clarke**  
US national reader training and education initiatives for Ga-68-labelled DOTATATE, DOTATOC, and PSMA

**Shamil D Cooray**
177Lu-DOTATATE peptide receptor chemo-radiouclide therapy (PRCRT) for SDHB-mutated metastatic paraganglioma: a case study

Satyawati Deswal
Influence of Post therapy 131I SPECT/CT on risk stratification in Patients with Differentiated thyroid cancer

Uta Eberlein
Patient dosimetry assessment with the somatostatin receptor antagonist 68Ga-labelled OPS202 in the first clinical study of gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Uta Eberlein
In-vitro dose calibration of the DNA damage assay for internal irradiation of blood lymphocytes with the PET nuclide 68Ga

Elisabeth Eppard
44Sc-PSMA-617 for pre-therapeutic dosimetry of prostate cancer

Edit Farkas
Physico-chemical characterization of Ga(III)-complexes formed with DATA chelators
Anne Laure ALG Giraudet
3D dosimetry using Monte-Carlo simulation (GATE) compared to biological toxicity observed in a first in man phase I trial of radioimmunotherapy targeting synovial sarcoma metastases (SS).

Steven J Goodman
Comparison of the Functional Response and Tumour Sink Effect in Patients with High and Low Liver Dose on the Dosimetry Scan Å

Simon Gray
Unusual Neuroendocrine tumour cases

Daniel Guendel
Evaluation of glomerular kidney function with 68Ga-DTPA in small animal PET/CT

Rod Hicks
Phase I/II open-label trial to evaluate the safety and preliminary efficacy of 177Lu-OPS201, a radiolabeled somatostatin receptor antagonist, in patients with somatostatin receptor-positive, progressive gastroenteropancreatic neuroendocrine tumors

Leena Hogan
Development and evaluation of the new ligand NOTET for the complexation ofÂ 68Ga

Charmaine Jeffery
A fully automated synthesis for the preparation of 64,67Cu-SARTATE using the iPHASE MultiSyn Radiosynthesiser

Amritjyot Kaur
Optimization of threshold method for volume and activity determinations by using SPECT Phantom for possible clinical use in predicting response to regeneration and targeted liver therapies.

Kamaleshwaran K Karuppusamy
Ga68-labelled PSMA ligand PET/CT in detecting recurrence of prostatic carcinoma in biochemical relapse and use of theranostics with LU 177 PSMA

Kamaleshwaran Koramadai K
Lutetium-177 PSMA Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Initial Indian Experience in coimbatore
Pavlo Korol
Quantitative surgical criteria of bone scintigraphy in patients during hip arthroplasty

Harshad R Kulkarni
Efficacy of peptide receptor radionuclide therapy in neuroendocrine neoplasms: the Bad Berka experience in 1048 patients over more than a decade

Harshad R Kulkarni
Establishing a routine method for the manual labeling of PSMA-I&T and PSMA-617 with Lutetium-177 under GMP conditions

Melissa J. Latter
Robust radiopharmaceutical production, proven quality and high activity — how to have it all

Thabo Lengana
The value of 68Ga-PSMA PET/CT in prostate cancer patients

Nigel A Lengkeek
Biodegradable star polymers: In vitro stability assessment of 64Cu- and 67Ga-NOTA stars

Rene Martin
Automated synthesis of 68Ga-PSMA-11 using the Scintomics® GRP module applying acetate buffer as an alternative to HEPES

Renata Mikolajczak
PSMA-11 in a dry kit formulation for 68Ga labelling

Renata Mikolajczak
A Novel CCK2/Gastrin Receptor-Localizing Peptide Probe for Personalized Diagnosis and Therapy of Medullary Thyroid Carcinoma - Gran-T-MTC enrolls patients in a multicentre Phase I Study

Dirk Mueller
Rapid Synthesis of 68Ga-MAA for routine application in lung perfusion imaging using PET/CT

Aravintho Natarajan
Initial experience of 68Ga-PSMA PET/CT imaging in evaluation of biochemical recurrence in prostate cancer patients.

Stephen Nocher
Theranostics — RBWH experience

Yaw Opoku-Damoah
The Quest to Achieving a Concerted Cancer Treatment: Challenges in Nanotheranostics Delivery

Sofia Papadopoulou
Chelator-free Radiolabeling of Iron Oxide Nanoparticles with 68Ga for Dual Modality PET/MR Imaging

Arvind ParMar
[64Cu]CuCl2 PET imaging for the evaluation of anticancer activity of Dextran-Catechin conjugate as a novel treatment for neuroblastoma
Brett M Paterson
Cyclen-based semicarbazone chelators of bismuth-213 for Î”-radiotherapy

Nisha Rani
Diagnostic performance of 99mTc-MDM brain SPECT in Glioma: A comparison with contrast enhanced MRI Imaging for diagnostic workup of primary/ residual/recurrent glioma

Arun Sasikumar
68Ga-PSMA PET/CT in lesion characterisation in suspected prostate carcinoma patients.

Arun Sasikumar
68Ga-PSMA PET/CT Brain imaging â€” a feasibility study.

Arun Sasikumar
68Ga-PSMA PET/CT in prostate cancer â€” A single centre experience from India.

Shamim Ahmed Shamim
To evaluate the role of Lutetium-177 (Lu-177) tin colloid radiosynovectomy (RSV) in patients with inflammatory knee joint conditions who are not responding to conventional modalities in a setup where Re-188 & Y-90 not available.

Deepa Singh
Ga-68-DOTANOC PET/CT scan- role in clinical management with advantage over conventional imaging in patients of neuroendocrine tumors

Deepa Singh
Role of Ga-68 DOTANOC PET/CT scan in chemotherapy response evaluation in patients with neuroblastoma

Deepa Singh
Lutetium-Â-177 (Lu-177) labeled EDTMP for metastatic bone pain palliation- initial experience at a tertiary care centre in India

Aviral Singh
Comparative assessment of skeletal uptake on 68Ga-PSMA PET/CT versus 18F-Fluoride PET/CT in prostate cancer

Aviral Singh
177Lu-PSMA radioligand therapy of prostate cancer in patients with single functioning kidney

Ashwani Sood
Safety and efficacy of peptide receptor radionuclide therapy (PRRT) using Lu-177 DOTATATE and capecitabine as a radiosensitizer in metastatic neuroendocrine tumors (NETs)

Janine Suthiram
Long-term evaluation of a 68Ga-PSMA-11 kit radiolabeling procedure and performance assessment for imaging GCPII/PSMA expression in patients with breast and prostate cancer

Teik Hin Tan
Efficacy and Safety of Peptide Receptor Radionuclide Therapy with/without Capcitabine in Asymptomatic Rectal Neuronedocrine Tumour: Malaysian Initial Experience
Imre Toth
Extraordinary Similarities of Formation and Dissociation Kinetics of FeIII- and GallI- TRAP-Pr Complexes

G. S. Tsebrikova
Investigation of 68Ga complexation with 1,7-diamino-4-oxyheptane-1,1,7,7-tetraphosphonic acid and preliminary in vivo study

Murat Tuncel
The diagnostic efficacy and clinical impact of PET-CT imaging with 68Ga-labelled PSMA ligand HBED-CC in patients with recurrent prostate cancer

Gianluca Valentini
Theranostic in patients with recurring Glioblastoma Multiforme (GBM): 64CuCl2

Daniel Valenzuela
Lu-177-DKFZ- PSMA-617Â treatment in castration resistantÂ metastaticÂ prostate cancer.Â Report of the first case in our Institution

Daniel Valenzuela
68Ga-DOTATATE PET- CT in the evaluation of Congenital Hyperinsulinism

Daniel Valenzuela
PET-CT with 68Ga-DOTA-peptides in non gastro-entero-pancreatic (nonGEP) neuroendocrine tumors (NET). Initial experience

Michael S Valic
A radio-pharmaceutical kit to prepare parenteral injections of a multimodal all-organic nanovesicle for "first-in-human" clinical studies in prostate cancer.

Roelf Valkema
Gallium-68-PSMA-HBED-CC PET/CT in patients with biochemical recurrence after radical prostatectomy or radiation therapy: potential impact onÂ treatment choice

Irina Velikyan

Irina Velikyan

Irina Velikyan
Critical aspects of 68Ga production and chemistry in relation to clinical applications

Finn E von Eyben
Salvage 177Lu-PSMA-617 therapy for a patient with chemotherapy-naÃ¨ve hormone-resistant oligometastatic prostate cancer
Mariza M Vorster
Preliminary results on the prognostic value of MTV and TLG on Ga-68-DOTATATE PET/CT in patients with Neuro-endocrine Tumours

Jairo Wagner
The halo-artifact leading to a potential false negative result of 68Ga-PSMA PET-CT. Â A case report.

Feng Wang
RGD imaging serve as a surrogate for molecular phenotyping and prognosis: A Prospective Study of 99mTc-3PRGD2 SPECT/CT in 226 Patients with Suspected Lung Cancer

Feng Wang
The Role of 99mTc-galacto-RGD2 SPECT/CT in the Clinical Management of Refractory Thyroid Cancer

Shiming Zang
68Ga-PSMA-11 PET/CT for the Staging and Risk Stratification of Chinese men with Prostate cancer

Chuan Zhang
Serum Chromogranin A in the Screening and Diagnosis of GEP-NENs

Gordon L Watkins
Â [90Y]DOTATOC manufacture of patient specific doses based on prior personal dosimetry.